Yorktown Management & Research Company’s Intellia Therapeutics NTLA Stock Holding History

Yorktown Management & Research Company’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,700	Closed	-$443K	–	206
2022 Q4	$443K	Sell	12,700 -2,620	-17%	-$125K	0.54%	64
2022 Q3	$857K	Hold	15,320	–	–	1.11%	12
2022 Q2	$793K	Sell	15,320 -2,000	-12%	-$102K	1.02%	13
2022 Q1	$1.26M	Sell	17,320 -1,980	-10%	-$168K	1.07%	14
2021 Q4	$2.28M	Buy	19,300 +1,000	+5%	+$125K	1.54%	6
2021 Q3	$2.46M	Buy	18,300 +600	+3%	+$90.8K	1.85%	3
2021 Q2	$2.87M	Buy	17,700 +1,700	+11%	+$132K	2.25%	1
2021 Q1	$1.28M	Buy	16,000 +1,000	+7%	+$67.1K	1.07%	12
2020 Q4	$816K	Sell	15,000 -1,000	-6%	-$36.3K	0.73%	20
2020 Q3	$318K	Buy	16,000 +2,800	+21%	+$58.4K	0.3%	181
2020 Q2	$277K	Buy	+13,200	New	+$224K	0.25%	217

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Yorktown Management & Research Company's NTLA Position: Q1 2023 in Review

Yorktown Management & Research Company sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 12,700 shares — an estimated $443K sold.

Yorktown Management & Research Company first reported a position in NTLA in Q2 2020 and held it in 11 quarters. The position peaked at $2.87M in Q2 2021. 291 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

Yorktown Management & Research Company reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
Yorktown Management & Research Company sold 12,700 Intellia Therapeutics shares in Q1 2023, an estimated $443K.
Yorktown Management & Research Company first reported a position in Intellia Therapeutics in Q2 2020 and held it in 11 quarters.
Yorktown Management & Research Company's Intellia Therapeutics position peaked at $2.87M in Q2 2021.
291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on Yorktown Management & Research Company's 13F filing for Q1 2023, filed 21 Apr 2023.